… informal support networks. The objective of this study was to characterize CP responsibilities, sources of support, and … Only 16 (11%) learned about PDP from a physician; communication challenges included perceived embarrassment or … Few CPs advocate for medications to control PDP, instead preferring non-pharmacological management strategies. Peer …

… for the management of Parkinson’s-related movement, or motor, symptoms.  The approval is an advance in focused … tremor, and in 2021 for additional motor symptoms and complications, like dyskinesia and ups and downs in symptom … whether you’re a candidate and guide you on when and where it may become available.  David Kumbroch Senior …

… Genetic mutations that activate LRRK2 are linked to familial Parkinson’s disease (PD). However, no clinically … In this study, we will develop and characterize novel compounds that inhibit either LRRK2 itself or a key … successful, the results will validate new LRRK targets and present a novel strategy for the development of PD …

… in pre-clinical models of the disease. We hope this treatment could halt or even reverse Parkinson's progression. … so we will design and test new molecules that act the same way, but are more drug-like, last longer, and could be … pill to stop brain inflammation. Impact on Diagnosis/Treatment of Parkinson's Disease: Labeled versions of the small …

… Study Rationale:                    Optogenetics has gained wide interest as a tool to understand … neuronal functions. This will first be tested in a pre-clinical PD model in which symptoms develop after … unintended targets. Next Steps for Development: Successful completion of this study will generate sufficient data to …

… Read some excerpts below, and see the full article to learn more about what it's like to participate.  The advancement of drug therapies into  … in participating in PD clinical trials but don't know where to start? Learn more on our clinical trials hub or …